Focal Epilepsy
The REALIZE study is a placebo-controlled clinical trial designed to test the effectiveness, safety and tolerability of investigational drug CVL-865, given as an oral pill, as a treatment for drug-resistant focal onset epilepsy. Participants will be randomly assigned to receive either CVL-865 or placebo, in addition to the medications they are already taking. The study aims to determine whether CVL-865 is effective in reducing seizure frequency compared to participants receiving placebo.
Participants who complete the study have the option to join an “open-label” extension study, in which all participants receive the investigational drug.